Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

Matchmaking for Shire and AbbVie already? Try Allergan (of course) and Pfizer

Now that AbbVie has said it wants to dump Shire, we could soon have two companies back on the market--and both could prove popular as the dust settles. In fact, as Bloomberg reports, AbbVie could make a decent second choice to AstraZeneca if Pfizer so chooses.

Once again, Roche breast cancer franchise shines, sending Q3 drug sales up 4%

Roche can thank its newly augmented breast cancer portfolio for powering third-quarter sales upward, far enough to surpass analyst estimates. And given the latest data on one of those drugs--Perjeta--more growth could be at hand.

FDA grants a combo-med exclusivity wish. Why is that a problem?

What's two extra years of exclusivity worth? Enough to spark a legal fight. The FDA posted new guidance on its website Friday, awarding certain combo meds 5 years of exclusivity compared with the previous three. Drugmakers had lobbied for the change, but the timing--and the wording--are bound to be controversial.

FDA reviewers say Pfizer's Chantix should keep its black box

FDA staffers aren't as impressed with new safety data on Chantix as Pfizer wants them to be. In briefing documents filed in advance of Thursday's advisory committee meeting, reviewers say the stop-smoking remedy should keep its black-box warning about potential psychiatric side effects.

Could Gilead's $95K nod trigger creative payment ideas? Ask J&J and AbbVie

Alarmed payers are gearing up for another hepatitis C battle. Now that Gilead Sciences' new two-in-one infection fighter Harvoni is approved--and with a $94,500 price--it's worth looking at some strategies payers have used with other hep C drugs, including Sovaldi, the single-agent sibling to Harvoni.

AstraZeneca photo campaign helps cancer patients swap stories on social media

AstraZeneca has launched a photo-sharing campaign on Twitter, Instagram and other social media sites to get women talking about their metastatic breast cancer (MBC).

Top U.S. execs flee Ranbaxy as Sun Pharma merger looms: paper

Ranbaxy Laboratories has been a steady source of bad news over the past several years. And now that India-based rival Sun Pharmacueticals is preparing to take over, the company's top U.S. leadership is throwing in the towel.

UPDATED: Texas AG: AstraZeneca paid $465K in kickbacks, committed fraud in Seroquel marketing

Texas Attorney General Greg Abbott has sued AstraZeneca for fraud, saying that AstraZeneca sales reps misled doctors and state Medicaid officials about Seroquel's side effects, paid kickbacks to two influential state decision-makers, and promoted the powerful antipsychotic for off-label uses.

Meda launches $276M rights issue to help pay for Rottapharm

As Sweden's Meda wraps up its buyout of the Italian drugmaker Rottapharm, it's rolling out a rights issue--to the tune of 2 billion kronor, or about $276 million--to help finance the deal.

Takeda wins temporary reprieve for controversial gout drug Colcrys

Turning the ancient gout remedy colchicine into an FDA-approved drug may not have been as costly an endeavor as developing a new med from scratch. But Takeda Pharmaceuticals still wants to reap brand-level sales for its version, dubbed Colcrys--and it's suing the FDA to make sure that happens.